Live tape
Top 8, mentions 7d6,690GOOGL1,243 mentions▲ +0.03AAPL1,187 mentions▲ +0.07NKE957 mentions+0.02ORCL794 mentions▲ +0.06NVDA778 mentions▲ +0.07META710 mentions▲ +0.05TSLA541 mentions▲ +0.06VOO480 mentions▲ +0.09

Equity · Healthcare

NBIX

Neurocrine Biosciences, Inc. · NasdaqGS

$157 +1.21% 1D Finazon · prior-day close · Sep 10, 2026
Price · Chart
Our own end-of-day closes 49 sessions
$190 $150 15 Jun 10 Sep

The line runs $159.45 on 15 June through $157 on 10 September, on a scale from $150 to $190. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of NBIX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 49 sessions over that window: $159.45 on 15 June 2026 through $157 on 10 September 2026.

Market cap $16.0B
P/E (TTM) 24.5
52-week range $123 – $181
Avg volume 113.6K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 11, 2026

NBIX insider trades

SEC Form 4 · last 90 days · newest reported trade 9 Sep 2026
Open-market buys 0
Open-market sells 9
Net sold $7.45M
Non-trade filings 11
Date Insider Type Shares Value
09 Sep 2026 BENEVICH ERIC Chief Commercial Officer Sell 2,154 $333K
28 Jul 2026 Norwalk Leslie V Director Sell 1,250 $228K
10 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 4,367 $791K
09 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 8,433 $1.51M
09 Jul 2026 Lippoldt Darin Chief Legal Officer Sell 10,000 $1.80M
08 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 2,737 $489K
07 Jul 2026 Delaet Ingrid Chief Regulatory Officer Sell 3,401 $607K
29 Jun 2026 Lippoldt Darin Chief Legal Officer Sell 9,800 $1.67M
26 Jun 2026 Lippoldt Darin Chief Legal Officer Sell 200 $34K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
09 Sep 2026 BENEVICH ERIC Chief Commercial Officer Option exercise 3,194 $138K
02 Sep 2026 SHERWIN STEPHEN A Director Gift 1,000
04 Aug 2026 Onyia Jude Chief Scientific Officer Gift 2,409
29 Jul 2026 Norwalk Leslie V Director Option exercise 842 $117K
10 Jul 2026 Delaet Ingrid Chief Regulatory Officer Option exercise 4,367 $463K
09 Jul 2026 Delaet Ingrid Chief Regulatory Officer Option exercise 8,433 $873K
09 Jul 2026 Lippoldt Darin Chief Legal Officer Option exercise 10,000 $815K
08 Jul 2026 Delaet Ingrid Chief Regulatory Officer Option exercise 2,737 $283K
07 Jul 2026 Delaet Ingrid Chief Regulatory Officer Option exercise 3,401 $352K
29 Jun 2026 Lippoldt Darin Chief Legal Officer Option exercise 9,800 $799K
26 Jun 2026 Lippoldt Darin Chief Legal Officer Option exercise 200 $16K

NBIX reported financials

SEC EDGAR XBRL

NBIX reported revenue of $2.9B for the fiscal year ended 31 Dec 2025. Net income over the same period was $478.6M.

Figure Reported Period
Revenue $2.9B 31 Dec 2025 fiscal year
Net income $478.6M 31 Dec 2025 fiscal year
Diluted EPS $4.67 31 Dec 2025 fiscal year
Total assets $5.4B 30 Jun 2026 at period end
Total equity $3.7B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

NBIX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $1.39 —
31 Mar 2026 Q1 2026 $1.91 —
31 Dec 2025 FY 2025 $4.67 —
30 Sep 2025 Q3 2025 $2.04 —
30 Jun 2025 Q2 2025 $1.06 —
31 Mar 2025 Q1 2025 $0.08 —
31 Dec 2024 FY 2024 $3.29 —
30 Sep 2024 Q3 2024 $1.24 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

NBIX institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a NBIX position for the quarter ended 30 Jun 2026 — a combined $1.6B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
AQR Capital Management Held (±25%) −22.7% shares 3,818,037 $643.5M
Renaissance Technologies Held (±25%) −3.4% shares 2,335,897 $393.7M
Two Sigma Investments Trimmed −32.2% shares 2,076,260 $349.9M
Man Group Added +44.5% shares 601,019 $101.3M
Marshall Wace Trimmed −46.8% shares 270,754 $45.6M
Bridgewater Associates Added +38.8% shares 205,677 $34.7M
Fisher Asset Management Held (±25%) +10.5% shares 135,104 $22.8M
Citadel Advisors Trimmed −79.5% shares 11,863 $2.0M
Millennium Management Trimmed −99.1% shares 11,585 $2.0M
D. E. Shaw & Co. Trimmed −93.7% shares 5,599 $944K

Source: SEC EDGAR 13F filings

NBIX fails-to-deliver

SEC CNS data

On 12 Aug 2026, 20 shares of NBIX failed to deliver (about $3K).

Settlement date Shares failed Notional % of shares out
12 Aug 2026 20 $3K <0.001%
07 Aug 2026 1 $160 <0.001%
03 Aug 2026 5,960 $994K 0.006%
29 Jul 2026 33 $6K <0.001%

Source: SEC fails-to-deliver (CNS) data